Kiora Pharmaceuticals Inc (KPRX) stock
KPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as KPHMW
$0.93−0.05 (-5.30%)
Close on Nov 17, 2026Market cap $4.11MP/E –Yield –
Kiora Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Kiora Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $9.86M, up 6.8% year over year. For fiscal 2025 it was $10.78M, up 37.5% from the year before. Over ten years it grew 14.8% a year on average. The highest annual figure on record is $10.78M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.78M | +37.5% |
| FY2024 | Dec 31, 2024 | $7.84M | +94.7% |
| FY2023 | Dec 31, 2023 | $4.03M | +16.8% |
| FY2022 | Dec 31, 2022 | $3.45M | -35.5% |
| FY2021 | Dec 31, 2021 | $5.35M | +50.0% |
| FY2020 | Dec 31, 2020 | $3.57M | -33.8% |
| FY2019 | Dec 31, 2019 | $5.39M | -33.1% |
| FY2018 | Dec 31, 2018 | $8.06M | -22.0% |
| FY2017 | Dec 31, 2017 | $10.33M | +22.7% |
| FY2016 | Dec 31, 2016 | $8.42M | +210.0% |
| FY2015 | Dec 31, 2015 | $2.72M | +411.6% |
| FY2014 | Dec 31, 2014 | $531.12K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.08M | -19.8% |
| Q1 FY2026 | Mar 31, 2026 | $2.12M | -16.1% |
| Q4 FY2025 | Dec 31, 2025 | $2.93M | +52.2% |
| Q3 FY2025 | Sep 30, 2025 | $2.73M | +24.9% |
| Q2 FY2025 | Jun 30, 2025 | $2.59M | +26.4% |
| Q1 FY2025 | Mar 31, 2025 | $2.53M | +50.3% |
| Q4 FY2024 | Dec 31, 2024 | $1.92M | +73.1% |
| Q3 FY2024 | Sep 30, 2024 | $2.18M | +101.4% |
| Q2 FY2024 | Jun 30, 2024 | $2.05M | +47.2% |
| Q1 FY2024 | Mar 31, 2024 | $1.68M | +284.3% |
| Q4 FY2023 | Dec 31, 2023 | $1.11M | +32.1% |
| Q3 FY2023 | Sep 30, 2023 | $1.09M | -18.6% |
| Q2 FY2023 | Jun 30, 2023 | $1.39M | +145.4% |
| Q1 FY2023 | Mar 31, 2023 | $438.28K | -38.1% |
| Q4 FY2022 | Dec 31, 2022 | $841.62K | -16.0% |
| Q3 FY2022 | Sep 30, 2022 | $1.33M | -18.2% |
| Q2 FY2022 | Jun 30, 2022 | $567.23K | -60.6% |
| Q1 FY2022 | Mar 31, 2022 | $707.93K | -44.7% |
| Q4 FY2021 | Dec 31, 2021 | $1.00M | -0.9% |
| Q3 FY2021 | Sep 30, 2021 | $1.63M | +65.2% |
| Q2 FY2021 | Jun 30, 2021 | $1.44M | +128.2% |
| Q1 FY2021 | Mar 31, 2021 | $1.28M | +36.5% |
| Q4 FY2020 | Dec 31, 2020 | $1.01M | -32.5% |
| Q3 FY2020 | Sep 30, 2020 | $985.88K | -59.0% |
| Q2 FY2020 | Jun 30, 2020 | $631.11K | -17.4% |
| Q1 FY2020 | Mar 31, 2020 | $938.04K | +30.0% |
| Q4 FY2019 | Dec 31, 2019 | $1.50M | +4.2% |
| Q3 FY2019 | Sep 30, 2019 | $2.41M | +6.5% |
| Q2 FY2019 | Jun 30, 2019 | $763.90K | -58.4% |
| Q1 FY2019 | Mar 31, 2019 | $721.48K | -71.4% |
| Q4 FY2018 | Dec 31, 2018 | $1.44M | -53.3% |
| Q3 FY2018 | Sep 30, 2018 | $2.26M | -28.9% |
| Q2 FY2018 | Jun 30, 2018 | $1.84M | -18.8% |
| Q1 FY2018 | Mar 31, 2018 | $2.52M | +38.9% |
| Q4 FY2017 | Dec 31, 2017 | $3.08M | +19.4% |
| Q3 FY2017 | Sep 30, 2017 | $3.18M | +29.7% |
| Q2 FY2017 | Jun 30, 2017 | $2.26M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.82M | – |
| Q4 FY2016 | Dec 31, 2016 | $2.58M | – |
| Q3 FY2016 | Sep 30, 2016 | $2.45M | – |
See a number that looks wrong?